Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.

[1]  G. Papatheodoridis,et al.  Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. , 2013, World journal of gastroenterology.

[2]  Yoshiyuki Suzuki,et al.  Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection , 2013, Hepatology.

[3]  V. Wong,et al.  Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. , 2013, Gastroenterology.

[4]  Kenta Yamamoto,et al.  Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. , 2013, Journal of hepatology.

[5]  John F. Flaherty,et al.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.

[6]  Y. Liaw,et al.  Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open‐label study , 2011, Hepatology.

[7]  Vincent Wai-Sun Wong,et al.  Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. , 2011, The Lancet. Oncology.

[8]  G. Touloumi,et al.  Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study , 2011, Gut.

[9]  M. Buti,et al.  Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease , 2011, Hepatology.

[10]  A. Lok,et al.  Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. , 2010, Journal of hepatology.

[11]  V. Wong,et al.  Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Fattovich,et al.  Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. , 2008, Journal of hepatology.

[13]  M. Yuen,et al.  Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease , 2007, Antiviral therapy.

[14]  George Kitis,et al.  Outcome of hepatitis B e antigen–negative chronic hepatitis B on long‐term nucleos(t)ide analog therapy starting with lamivudine , 2005, Hepatology.

[15]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[16]  Pietro Andreone,et al.  Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine , 2004, Hepatology.

[17]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[18]  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. , 2012, Journal of hepatology.

[19]  M. Yuen,et al.  Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. , 2009, Journal of hepatology.